# Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects

> **NCT03980080** · PHASE1 · COMPLETED · sponsor: **OSE Immunotherapeutics** · enrollment: 63 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** OSE-127
- **DRUG:** Placebo
- **DRUG:** OSE-127

## Key facts

- **NCT ID:** NCT03980080
- **Lead sponsor:** OSE Immunotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-19
- **Primary completion:** 2019-11-04
- **Final completion:** 2019-11-04
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2019-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03980080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03980080, "Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03980080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*